Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep-Oct;37(5):2224-2228.
doi: 10.21873/invivo.13323.

Cetuximab Plus Concurrent Radiotherapy in Patients With Nasopharyngeal Carcinoma

Moriyasu Yamauchi  1 , Yuki Sato  2 , Tomoya Ishida  2 , Akimichi Minesaki  2 , Eriko Shimazaki  2 , Yuichiro Kuratomi  2
Affiliations

Cetuximab Plus Concurrent Radiotherapy in Patients With Nasopharyngeal Carcinoma

Moriyasu Yamauchi et al. In Vivo. 2023 Sep-Oct.

Abstract

Background/aim: Several reports have evaluated the efficacy and safety of concurrent radiotherapy with cetuximab (BRT) in patients with nasopharyngeal carcinoma (NPC). Combination therapy with cetuximab can be a treatment option for NPC. Although clinical data regarding the efficacy and safety of BRT without induction chemotherapy (ICT) or adjuvant chemotherapy is essential for the development of new therapeutic strategies, such data are rarely reported.

Patients and methods: We retrospectively investigated a series of patients with NPC treated in our institution to evaluate the efficacy and safety of BRT. Eleven patients with newly diagnosed NPC were identified from an inpatient database from July 2015 to April 2018. Seven patients who received BRT were reviewed.

Results: All patients completed BRT without cessation of treatment. Six (85.7%) patients achieved a complete response and one (14.3%) achieved stable disease. The response rate was 85.7%. All patients with ≤T3 disease achieved a complete response. Both patients with T3 disease developed local recurrence, and one of the four patients with T1-2 disease developed distant metastases. The 1- and 3-year overall survival rates were 85.7% and 47.6%, respectively. The most common adverse events (AEs) were pharyngeal mucositis (100%), radiation dermatitis (100%), anorexia (28.6%), weight loss (28.6%), acneiform rash (28.6%), and dry mouth (28.6%). Grade 3 AEs were pharyngeal mucositis (42.9%), radiation dermatitis (28.6%), and anorexia (14.3%). No grade 4/5 AEs were observed.

Conclusion: BRT for NPC was tolerable, but our findings suggest that BRT without induction chemotherapy or adjuvant chemotherapy is insufficient at least for ≥T3 disease.

Keywords: BRT; Cetuximab; nasopharyngeal carcinoma; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The Authors have no conflicts of interest to disclose with respect to the publication of this paper.

Figures

Figure 1
Figure 1. Kaplan-Meier estimates for overall survival.
See this image and copyright information in PMC

References

    1. Chen L, Gallicchio L, Boyd-Lindsley K, Tao XG, Robinson KA, Lam TK, Herman JG, Caulfield LE, Guallar E, Alberg AJ. Alcohol consumption and the risk of nasopharyngeal carcinoma: a systematic review. Nutr Cancer. 2009;61(1):1–15. doi: 10.1080/01635580802372633. - DOI - PMC - PubMed
    1. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–1024. doi: 10.1016/s0140-6736(15)00055-0. - DOI - PubMed
    1. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28. doi: 10.1016/s1470-2045(09)70311-0. - DOI - PubMed
    1. Tulalamba W, Janvilisri T. Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers. Int J Cell Biol. 2012;2012:594681. doi: 10.1155/2012/594681. - DOI - PMC - PubMed
    1. Shen J, Sun C, Zhou M, Zhang Z. Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis. Onco Targets Ther. 2019;12:2477–2494. doi: 10.2147/OTT.S193039. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources